# A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

> **NCT04093570** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Taiho Oncology, Inc.** · enrollment: 332 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** ASTX727

## Key facts

- **NCT ID:** NCT04093570
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2019-09-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04093570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04093570, "A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04093570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*